Needham analyst Matthew Shea initiated coverage of Astrana Health (ASTH) with a Buy rating and $28 price target The firm believes value-based care “is at an inflection point,” with higher reimbursement rates and heightened utilization working their way into benchmarks. Astrana is “leaning into full risk deals at a greater rate than others in our coverage,” the analyst tells investors in a research note. Needham believes the shift to risk and organic growth opportunities in core and emerging markets can drive 20%-30% growth for Astrana Health over the long term.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market Opportunities
- Astrana Health price target lowered to $37 from $44 at Jefferies
- Astrana Health price target lowered to $26 from $36 at Barclays
- Astrana Health price target lowered to $35 from $40 at TD Cowen
- Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth